Table 2.
Clinical characteristics and antibody specificity of lesion antibody-secreting cells in salivary glands
| Patient ID | S3 | S10 | LB32 | LB73 | LB90 | LB117 | LB101 | LB93 | LB17 | LB25 | LB46 | LB19 | LB23 | LB47 | LB48 |
| Age, sex | 51, F | 71, F | 31, F | 29, F | 70, F | 70, F | 65, F | 65, F | 47, F | 86, F | 50, F | 54, F | 60, F | 38, F | 47, F |
| Disease | sSS, PBC, MCTD |
pSS | pSS | sSS, SSc | pSS | pSS | sSS, PMR | pSS | pSS | pSS | pSS | pSS | pSS | nonSS | nonSS |
| Anti-CENP-B antibody | + | + | + | + | + | + | + | + | NA | NA | NA | NA | – | – | NA |
| ANA discrete-speckled | - ＊ | + | + | + | + | + | + | + | – | – | – | – | – | – | – |
| ANA | >2560 Sp+C | 640 H+D | 640 H+D+N | 2560 D | 320 H+D | 160 D | 320 D | 160 D | 40 Sp | 80 H+Sp | 80 Sp | <40 | <40 | 40 H+Sp | 80 H+Sp |
| Anti-SSA antibody | + | + | – | – | – | + | – | – | + | + | + | – | – | – | – |
| Anti-SSB antibody | + | – | – | – | – | – | – | – | + | + | – | – | – | – | – |
| Rheumatoid factor | + | + | – | + | NA | + | – | – | – | – | + | + | – | – | – |
| Greenspan grade | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 1 | 3 | 4 | 4 | 3 | 4 | 2 | 1 |
| Medication | ＋ † | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Extraglandular symptom | PH | – | Erythema | – | – | – | – | – | – | – | – | – | – | – | – |
| Antibody-secreting cell | |||||||||||||||
| CBX5 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| CENP-A | ± | ± | – | – | ± | ± | – | – | – | – | – | – | – | – | – |
| CENP-B | – | ± | – | ± | – | ± | – | – | – | – | – | – | – | – | – |
| CENP-C | +++ | +++ | ++ | +++ | ++ | + | – | – | – | – | – | – | – | – | – |
| CENP-HIKM | +++ | – | ++ | ± | +++ | +++ | – | – | – | – | – | – | – | – | – |
| CENP-TWSX | – | – | – | – | – | ± | – | – | ± | ± | – | – | – | – | – |
| CENP-OPQUR | ++ | – | – | – | – | + | – | – | – | – | – | – | – | – | – |
| CENP-LN | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| MIS12 complex | +++ | ++ | +++ | +++ | +++ | +++ | – | – | – | – | – | – | – | – | – |
| NDC80 complex | + | + | – | ++ | – | – | – | – | – | – | – | – | – | – | – |
| KNL1 complex | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Astrin-SKAP complex | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| CENP-E | – | – | – | – | – | ± | – | – | – | – | – | – | – | – | – |
| CENP-F | – | – | – | ± | – | – | – | – | – | – | – | – | – | – | – |
| RZZ complex | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Ska1 complex | – | – | – | ± | – | – | – | – | – | – | – | – | – | – | – |
Slides were examined at a magnification of ×200. –, undetectable; ±, one cell in multiple fields; +, 1–3 cells in one field; ++, 4–8 cells in one field; +++,>8 cells in one field
The patient IDs correspond to those in our previous study.17
*ACA converted to positive after 1 year of immunosuppressive therapy.
†Treated with prednisolone 10 mg/day.
C, cytosol; D, discrete-speckled; F, female; H, homogeneous; LB, lip biopsy; MCTD, mixed connective tissue disease; N, nucleolar; NA, not assessed; PH, pulmonary hypertension; PMR, polymyalgia rheumatica; pSS, primary Sjögren’s syndrome; RZZ, Rod-Zw10-Zwilch; S, salivary gland; Sp, speckled; SS, Sjögren’s syndrome; sSS, secondary Sjögren’s syndrome.